#386 - Aging clocks—what they measure, how they work, and their clinical and real-world relevance
Episode
42 min
Read time
2 min
Topics
Health & Wellness, Leadership, Psychology & Behavior
AI-Generated Summary
Key Takeaways
- ✓Epigenetic Clock Mechanics: Aging clocks measure methylation at CpG sites—locations where cytosine links to guanine on the DNA backbone—across hundreds of thousands of genomic positions, then compress that data into a single biological age score. These methylation patterns shift predictably with age and are influenced by smoking, inflammation, and metabolic health, making them molecular records of biological wear.
- ✓Clock Discordance Problem: Four leading clocks—PhenoAge (500 CpG sites), GrimAge (1,000 CpG sites), GrimAge2, and DunedinPACE (173 CpG sites)—produced conflicting results in the DO Health trial. Omega-3 moved three of four clocks; GrimAge showed no effect from any intervention. Before ordering a clock test, identify which specific clock a company uses, since different clocks capture different biological pathways and produce meaningfully different conclusions.
- ✓Omega-3 Signal Across Clocks: In the DO Health trial, 1 gram daily of EPA/DHA (330mg EPA, 660mg DHA from marine algae) over three years produced statistically significant reductions in biological age across three of four epigenetic clocks. The magnitude translated to roughly three months of slowed aging over three years—a modest but consistent signal suggesting omega-3 status meaningfully influences methylation patterns tied to aging biomarkers.
- ✓Noise Limitations Before Purchasing Tests: Two distinct noise sources undermine individual-level aging clock reliability: biological noise from transient inflammation, recent illness, or post-exercise recovery that temporarily shifts methylation readings, and technical noise from sample handling, DNA extraction variability, immune cell composition in blood, and batch effects on methylation arrays. The same blood sample sent to multiple labs can return different biological age scores.
- ✓Validated Biomarkers Still Outperform Clocks: Life insurance actuarial models predict population mortality with under 1% deviation using blood pressure, glucose, lipids, smoking status, and basic fitness metrics—without incorporating any commercial or research-grade aging clocks. Until epigenetic clocks demonstrate direct links to hard outcomes like cancer, cardiovascular disease, or dementia incidence, established clinical biomarkers provide more actionable individual health guidance.
What It Covers
Peter Attia examines aging clocks—epigenetic tools that estimate biological age via DNA methylation patterns—analyzing two studies: the DO Health randomized trial testing omega-3, vitamin D, and exercise across four clocks, and a brain MRI study measuring pace of aging to predict dementia risk and mortality.
Key Questions Answered
- •Epigenetic Clock Mechanics: Aging clocks measure methylation at CpG sites—locations where cytosine links to guanine on the DNA backbone—across hundreds of thousands of genomic positions, then compress that data into a single biological age score. These methylation patterns shift predictably with age and are influenced by smoking, inflammation, and metabolic health, making them molecular records of biological wear.
- •Clock Discordance Problem: Four leading clocks—PhenoAge (500 CpG sites), GrimAge (1,000 CpG sites), GrimAge2, and DunedinPACE (173 CpG sites)—produced conflicting results in the DO Health trial. Omega-3 moved three of four clocks; GrimAge showed no effect from any intervention. Before ordering a clock test, identify which specific clock a company uses, since different clocks capture different biological pathways and produce meaningfully different conclusions.
- •Omega-3 Signal Across Clocks: In the DO Health trial, 1 gram daily of EPA/DHA (330mg EPA, 660mg DHA from marine algae) over three years produced statistically significant reductions in biological age across three of four epigenetic clocks. The magnitude translated to roughly three months of slowed aging over three years—a modest but consistent signal suggesting omega-3 status meaningfully influences methylation patterns tied to aging biomarkers.
- •Noise Limitations Before Purchasing Tests: Two distinct noise sources undermine individual-level aging clock reliability: biological noise from transient inflammation, recent illness, or post-exercise recovery that temporarily shifts methylation readings, and technical noise from sample handling, DNA extraction variability, immune cell composition in blood, and batch effects on methylation arrays. The same blood sample sent to multiple labs can return different biological age scores.
- •Validated Biomarkers Still Outperform Clocks: Life insurance actuarial models predict population mortality with under 1% deviation using blood pressure, glucose, lipids, smoking status, and basic fitness metrics—without incorporating any commercial or research-grade aging clocks. Until epigenetic clocks demonstrate direct links to hard outcomes like cancer, cardiovascular disease, or dementia incidence, established clinical biomarkers provide more actionable individual health guidance.
Notable Moment
When Attia contacted a senior life insurance executive, he learned these companies predict mortality with such precision that a 1% deviation in expected payouts would be considered extraordinary—and they achieve this without using any biological aging clocks, relying entirely on conventional health metrics.
Episode Transcript
Hey, everyone. Welcome to the Drive podcast. I'm your host, Peter Attia. This podcast, my website, and my weekly newsletter all focus on the goal of translating the science of longevity into something accessible for everyone. Our goal is to provide the best content in health and wellness, and we've established a great team of analysts to make this happen. It is extremely important to me to provide all of this content without relying on paid ads. To do this, our work is made entirely possible by our members. And in return, we offer exclusive member only content and benefits above and beyond what is available for free. If you want to take your knowledge of this space to the next level, it's our goal to ensure members get back much more than the price of the subscription. If you want to learn more about the benefits of our premium membership, head over to peteratiamd.com forward slash subscribe. Welcome to a special episode of The Drive. In this episode, I take a different approach where I walk through a single topic in-depth, and this is a topic that many of you have been asking about, aging clocks. So in this episode, I explain what aging clocks are and the difference between chronological age and biological age along with the difference between those and something called the pace of aging, how epigenetic clocks work, and what they may actually be measuring. I'm gonna talk about a randomized control trial that used three very simple interventions and tested four of the most common aging clocks. I'm gonna also talk about another study that used brain imaging via MRI to study the pace of aging and see what could be gleaned about not just the risk of dementia but also mortality. I'll discuss the biggest limitation in the field, which is whether changing a clock actually changes meaningful clinical outcomes. So without further delay, I hope you enjoy this special episode of The Drive. So if you wanted to run the perfect antiaging trial, you know, the endpoints would be really obvious. You know, you'd wanna see fewer heart attacks, fewer cancers, fewer dementia diagnoses, and ultimately, fewer deaths. So we would call these hard outcomes real outcomes that matter. These are the clinical outcomes that we all care about. Now, of course, the reason we don't see these trials is that they would take a very long time. These would literally be twenty year trials, and with that would come in or enormous complexity and cost. Furthermore, it would be very difficult to ensure that whatever intervention you put in place was being put in place for the duration of this time. I mean, that would be not that hard to do if it was a drug trial because it's relatively easy to take a drug, drug, but it would be more challenging for a lifestyle trial. Okay. So every few years, the the fields of geroscience and medicine and cardiovascular disease, …
Get the full transcript (7,116 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 39-minute episode.
Get The Peter Attia Drive summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from The Peter Attia Drive
#404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies | Linus Abrams, M.D.
Aug 17 · 137 min
Huberman Lab
Restore Youthfulness & Vitality to the Aging Brain & Body | Dr. Tony Wyss-Coray
Feb 23
More from The Peter Attia Drive
#403 ‒ Peptides: separating scientific promise from marketing hype
Aug 10 · 53 min
The Rich Roll Podcast
AMA: Alex Pretti, Alex Honnold, Peter Attia, & Finding Hope In Dark Times
Feb 12
Books, tools, and gear mentioned in this episode
SignalCast may earn commission on purchases via these links.
other
“Four leading clocks—PhenoAge (500 CpG sites), GrimAge (1,000 CpG sites), GrimAge2, and DunedinPACE (173 CpG sites)—produced conflicting results in the DO Health trial.”
“Four leading clocks—PhenoAge (500 CpG sites), GrimAge (1,000 CpG sites), GrimAge2, and DunedinPACE (173 CpG sites)—produced conflicting results in the DO Health trial.”
“Four leading clocks—PhenoAge (500 CpG sites), GrimAge (1,000 CpG sites), GrimAge2, and DunedinPACE (173 CpG sites)—produced conflicting results in the DO Health trial.”
“Four leading clocks—PhenoAge (500 CpG sites), GrimAge (1,000 CpG sites), GrimAge2, and DunedinPACE (173 CpG sites)—produced conflicting results in the DO Health trial.”
More from The Peter Attia Drive
We summarize every new episode. Want them in your inbox?
#404 ‒ Mental health beyond neurotransmitters: the role of hormones in psychiatry, why symptom reduction isn't enough, and the future of psychedelic therapies | Linus Abrams, M.D.
#403 ‒ Peptides: separating scientific promise from marketing hype
#402 ‒ NMR blood analysis: how heart disease risk, insulin resistance, inflammation, and mortality risk can be assessed from a single blood sample | Jim Otvos, Ph.D.
#401 ‒ How curiosity transforms medicine: extraordinary discoveries that changed modern healthcare
#400 ‒ AMA #87: Environmental pollution and longevity: air pollution, noise, light, EMFs, and practical strategies to mitigate health risks
Similar Episodes
Related episodes from other podcasts
Huberman Lab
Feb 23
Restore Youthfulness & Vitality to the Aging Brain & Body | Dr. Tony Wyss-Coray
The Rich Roll Podcast
Feb 12
AMA: Alex Pretti, Alex Honnold, Peter Attia, & Finding Hope In Dark Times
The Model Health Show
Jan 19
Science-Backed Methods That Extend Your Life Far More Than Genetics Ever Will
We Study Billionaires
Nov 5
TECH007: Longevity Roadmap w/ Seb Bunney (Tech Podcast)
Huberman Lab
Oct 30
Essentials: The Biology of Slowing & Reversing Aging | Dr. David Sinclair
Explore Related Topics
This podcast is featured in Best Health Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Health & Longevity Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into The Peter Attia Drive.
Every Monday, we deliver AI summaries of the latest episodes from The Peter Attia Drive and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime